Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Oxilofrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.64 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.64 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.64 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.64 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.64 |
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.57 |
| ▸ | OPRM1 known ✓ | P35372 | 4/20 | 0.57 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.57 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.57 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.57 |
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.54 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.54 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.54 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.54 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.50 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.48 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 0.47 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxilofrine SCHEMBL5174274 | 1.00 | KMT2A (0.68) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Oxilofrine SCHEMBL14465574 | 0.98 | ADRA1A (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Oxilofrine SCHEMBL147458 | 0.98 | ADRA1A (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Oxilofrine SCHEMBL14153976 | 0.98 | ADRA1A (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Oxilofrine SCHEMBL4256893 | 0.98 | ADRA1A (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Oxilofrine SCHEMBL5173040 | 0.98 | ADRA1A (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| SCHEMBL23999280 | 0.81 | CYP2D6 (0.67) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Pseudoephedrine SCHEMBL118099 | 0.81 | KMT2A (1.00) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| SCHEMBL20690347 | 0.81 | HIF1A (0.56) | KMT2AMEN1HBBADRA1ACYP2D6 | |
| Racephedrine SCHEMBL22823 | 0.81 | KMT2A (1.00) | KMT2AMEN1HBBADRA1ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025131826-A1 | CURABLE POLYMER COMPOSITIONS CONTAINING ISOCYANATES, ALDIMINES AND COMPOUNDS WITH ACTIVATED METHYLENE GROUPS | SIKA TECHNOLOGY AG (CH) | 2025-06-26 | — | — | WO | claimed |
| EP-4574867-A1 | CURABLE POLYMER COMPOSITIONS CONTAINING ISOCYANATES, ALDIMINES AND COMPOUNDS HAVING ACTIVATED METHYLENE GROUPS | Sika Technology AG (CH) | 2025-06-25 | — | — | EP | claimed |
| EP-3820966-B1 | MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2022-06-08 | — | — | EP | claimed |
| US-20260070867-A1 | BINAPHTHYL COMPOUNDS AND THERMOPLASTIC RESINS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2026-03-12 | — | — | US | disclosed |
| EP-4662286-A1 | PROCESS FOR PRODUCING A HYBRID NON-ISOCYANATE-CONTAINING POLYURETHANE | Nolax AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| EP-4626854-A1 | BINAPHTHYL COMPOUNDS AND THERMOPLASTIC RESINS | Mitsubishi Gas Chemical Company, Inc. (JP) | 2025-10-08 | — | — | EP | disclosed |
| EP-4594286-A1 | OLIGOMERIC BINAPHTYL COMPOUNDS AND THERMOPLASTIC RESINS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2025-08-06 | — | — | EP | disclosed |
| US-20250236629-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND RELATED USES | OXFORD FINANCE LLC | 2025-07-24 | — | — | US | disclosed |
| EP-4514787-A1 | OLIGOMERIC BINAPHTHYL COMPOUNDS AND THERMOPLASTIC RESINS | Reuter Chemische Apparatebau e.K. (DE) | 2025-03-05 | — | — | EP | disclosed |
| US-12112789-B2 | Apparatuses and methods for input buffer enable clock synchronization | MICRON TECHNOLOGY, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| WO-2024165634-A1 | PROCESS FOR PRODUCING A HYBRID NON-ISOCYANATE-CONTAINING POLYURETHANE | NOLAX AG (CH) | 2024-08-15 | — | — | WO | disclosed |
| WO-2023208837-A1 | OLIGOMERIC BINAPHTHYL COMPOUNDS AND THERMOPLASTIC RESINS | REUTER CHEMISCHE APPARATEBAU E.K. (DE) | 2023-11-02 | — | — | WO | disclosed |
| US-20230203059-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | BIOPOLAR HONGYE (NANTONG) PHARMACEUTICAL CO. LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-4175491-A1 | KIT FOR COLORING TUBE FEEDS | Fresenius Kabi Deutschland GmbH (DE) | 2023-05-10 | — | — | EP | disclosed |
| EP-4159738-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | Biopolar Hongye (Guangdong) Pharmaceutical Co. Ltd (CN) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023036868-A1 | (HET)ARYL SUBSTITUTED BISPHENOL COMPOUNDS AND THERMOPLASTIC RESINS | REUTER CHEMISCHE APPARATEBAU E.K. (DE) | 2023-03-16 | — | — | WO | disclosed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| EP-4076667-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | Erasca, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022108439-A1 | METHOD AND COMPOSITIONS FOR SKIN MICROBIOME NORMALIZATION IN SENSITIVE SKIN | WIPRO MANUFACTURING SERVICES SDN. BHD. (MY) | 2022-05-27 | — | — | WO | disclosed |
| CN-215610003-U | High temperature resistant dust removal filter bag of circulated use | 临沂市能量环保材料科技有限公司 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236629-A1 | MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND RELATED USES | HCRTR2, HCRTR1, CRHR2 | ADRA1A 228/4885ADRA2C 21/4885HTR2A 72/4885 |
| US-20260070867-A1 | BINAPHTHYL COMPOUNDS AND THERMOPLASTIC RESINS | CBR1, CBR3, SCO2 | ADRA1A 2641/4885ADRA2C 1804/4885HTR2A 2619/4885 |
| US-20230203059-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | JAK3, JAK2, JAK1 | ADRA1A 4252/4885ADRA2C 3817/4885HTR2A 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.